Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2351-2360 Newer>

The Motley Fool September 2, 2005 Stephen D. Simpson	Can Arrow International Straighten Up? Can the medical products maker overcome capacity constraints and get the top line flying again? Investors, take note.
The Motley Fool September 2, 2005 Rich Duprey	An Opportunity Not to Forget Japanese pharmaceutical Eisai targets another segment of the growing Alzheimer's market. Investors, take note.
The Motley Fool September 2, 2005 Rich Duprey	Will Flu Vaccine Catch Cold? The CDC says we may have as many as 97 million doses this year, but that's a best-case scenario. This year again, it's Chiron causing the uncertainty.
Pharmaceutical Executive September 1, 2005 Wilkenfeld & Braun-Davis	50 5 2005 Five things pharmaceutical companies can do to prepare for compliance in all 50 states.
Pharmaceutical Executive September 1, 2005 Bill Trombetta	2005 Industry Audit Who's really on top in the pharmaceutical industry?
Pharmaceutical Executive September 1, 2005 Parker & Amar	Building Blockbusters The most lucrative new drugs are often less glamorous than first-in-class new molecular entities. And they are much less risky.
Pharmaceutical Executive September 1, 2005 Tenaglia & Angelastro	No Margin for Error Pharmaceutical companies that will be forced to cut back on sales and marketing spending must focus on value, not volume. Here's how to reduce your spending where it matters the least.
Pharmaceutical Executive September 1, 2005 Mattingly & Saxberg	Biomarkers Come of Age In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened - and what comes next.
Pharmaceutical Executive September 1, 2005 Nickum & Kelly	Missing the Mark(et) Pharmaceutical companies spend billions on data. Sales reps crowd the waiting rooms. So why is the doctor out?
Pharmaceutical Executive September 1, 2005 Jamie Hintlian	Track and Trace For radio frequency identification in pharma, the devil is in the details.
<Older 2351-2360 Newer> Return to current articles.